TY  -  
T1  - Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland 
SN  -  /  
UR  - http://hdl.handle.net/10138/228671 
T3  -  
A1  - Soini, Erkki; Asseburg, Christian; Taiha, Maarit; Puolakka, Kari; Purcaru, Oana; Luosujärvi, Riitta 
A2  -  
PB  -  
Y1  - 2017 
LA  - eng 
AB  - To model the American College of Rheumatology (ACR) outcomes, cost-effectiveness, and budget impact of certolizumab pegol (CZP) (with and without a hypothetical risk-sharing scheme at treatment initiation for biologic-na <ve patients) versus the current mix of reimbursed biologics for treatment of moderate-to-severe rheumatoid arthritis (RA) in Finland. A probabilistic model with 12-week cycles and a societal approach was developed for the years 2015-2019, accounting for differences in ACR respo... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Biological therapies; Certolizumab pegol; Disease-modifying antirheumatic drugs; Health economics; Health policies; Rheumatoid arthritis; Rheumatology; MODIFYING ANTIRHEUMATIC DRUGS; 5-YEAR FOLLOW-UP; QUALITY-OF-LIFE; COST-EFFECTIVENESS; EULAR RECOMMENDATIONS; PRODUCTIVITY COSTS; DISEASE-ACTIVITY; 2013 UPDATE; REGISTER; BURDEN; 3121 General medicine, internal medicine and other clinical medicine; 317 Pharmacy 
N1  -   
PP  -  
ER  -